Abstract | Purpose: Using a composite endpoint, pooled data from two 12-week Phase III placebo-controlled trials (GOLDEN 3, NCT02347761; GOLDEN 4, NCT02347774) were analyzed to determine whether glycopyrrolate inhalation solution (25 mcg and 50 mcg) administered twice daily (BID) via the eFlow® Closed System nebulizer (GLY) reduced the risk of clinically important deterioration (CID) in patients with moderate-to-very-severe COPD. Methods: CID was defined as ≥100-mL decrease from baseline in post- bronchodilator trough forced expiratory volume in one second (FEV1), or ≥4-unit increase in baseline St. George's Respiratory Questionnaire (SGRQ) total score, or moderate/severe exacerbation. The relative treatment effect of GLY versus placebo on the odds of CID (any and by component endpoints) was expressed as the odds ratio (OR) and 95% confidence interval (CI). Subgroups categorized by age (<65/≥65 years), sex, smoking status (current/former), long-acting beta agonist (LABA) use, FEV1 (<50%/≥50%), and peak inspiratory flow rate (PIFR) (<60 L/min/≥60 L/min) were analyzed. Results: Compared to placebo, GLY 25 mcg and 50 mcg BID over 12 weeks significantly reduced the risk of CID by 50% (OR: 0.50 [0.37-0.68]) and 40% (OR: 0.60 [0.44-0.80]), respectively. Subjects treated with GLY 25 mcg BID were 59% less likely to experience CID in FEV1 (OR: 0.41 [0.27-0.62]) and 48% less likely to perceive CID in health status (OR: 0.52 [0.37-0.73]). Statistically significant reductions were also observed at the higher dose. The incidence of moderate/severe exacerbations was low and comparable among the cohorts. GLY 25 mcg BID was significantly more effective than placebo (p<0.05) in preventing CID irrespective of age, smoking status, LABA use, COPD severity, or PIFR. Subjects <65 years (OR 0.45 [0.29-0.68]) and those with PIFR <60 L/min (OR 0.36 [0.20-0.67]) exhibited the largest benefit. Conclusion: Nebulized GLY over 12 weeks significantly reduced the risk of CID and provided greater short-term stability in patients with moderate-to-very-severe COPD.
|
Authors | Edward M Kerwin, Lindsey Murray, Xiaoli Niu, Carole Dembek |
Journal | International journal of chronic obstructive pulmonary disease
(Int J Chron Obstruct Pulmon Dis)
Vol. 15
Pg. 2309-2318
( 2020)
ISSN: 1178-2005 [Electronic] New Zealand |
PMID | 33061349
(Publication Type: Journal Article, Randomized Controlled Trial)
|
Copyright | © 2020 Kerwin et al. |
Chemical References |
- Bronchodilator Agents
- Muscarinic Antagonists
- Glycopyrrolate
|
Topics |
- Administration, Inhalation
- Aged
- Bronchodilator Agents
(therapeutic use)
- Disease Progression
- Double-Blind Method
- Female
- Forced Expiratory Volume
(drug effects)
- Glycopyrrolate
(therapeutic use)
- Humans
- Muscarinic Antagonists
(therapeutic use)
- Pulmonary Disease, Chronic Obstructive
(diagnosis, drug therapy)
- Severity of Illness Index
- Treatment Outcome
|